文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

1.5特斯拉MR-linac前列腺癌SBRT亚分次工作流程缩小边缘后的急性毒性与生活质量

Acute toxicity and quality of life after margin reduction using a sub-fractionation workflow for stereotactic radiotherapy of localized prostate cancer on a 1.5 Tesla MR-linac.
PubMed 文献 · Radiother Oncol · 2025-03-13

该研究在1.5 T MR-linac上对局限期前列腺癌实施36.25 Gy/5次SBRT,比较PTV边缘从5 mm缩小至2-3 mm前后的急性毒性差异。倾向性评分匹配后每组106例,未观察到医生报告的毒性在任何随访点有统计学显著差异;患者报告泌尿刺激/梗阻生活质量在1个月时统计学显著但非临床显著升高。结论认为边缘缩小至5 mm以下似乎未降低急性毒性。

要点

  • PTV边缘从5 mm缩小至2-3 mm后,医生报告的GU和GI毒性在各随访点均无统计学显著差异。
  • 患者报告泌尿刺激/梗阻生活质量在1个月时统计学显著但非临床显著升高。
  • 总体评分在治疗期间和放疗后1个月下降,3个月时恢复至基线水平。

核心结论

  • 将PTV边缘缩小至5 mm以下似乎未降低局限期前列腺癌SBRT后的急性毒性。
  • 引入实时全面运动管理和前列腺门控可能进一步降低GU和GI毒性并改善治疗相关生活质量。

研究设计与样本

  • 在本中心实施亚分次工作流程以校正分次内运动,将PTV边缘从各向同性5 mm缩小至头尾和左右方向2 mm、前后方向3 mm。
  • 纳入患者接受1.5 T MR-linac上36.25 Gy分5次SBRT,PTV边缘为5 mm(标准边缘)或2-3 mm(紧缩边缘)。
  • 共识别299例 eligible 患者(紧缩边缘组193例,标准边缘组106例),经多重插补链式方程后倾向性评分匹配,212例(每组106例)纳入评估。
  • 主要终点为急性(放疗后90天)毒性,医生报告毒性采用CTCAE 5.0版GU和GI最高评分;患者报告毒性为次要终点,采用EPIC-26泌尿和肠道领域评分。
  • CTCAE评分采用Pearson卡方检验,EPIC-26评分采用Wilcoxon秩和检验。

主要发现

  • 匹配后每组106例,医生报告的毒性在任何随访点均未观察到统计学显著组间差异。
  • 患者报告泌尿刺激/梗阻生活质量在1个月时统计学显著但非临床显著升高。
  • 总体评分在治疗期间和放疗后1个月下降,但在放疗后3个月恢复至基线水平。

关键数值与推荐

  • 处方剂量为36.25 Gy分5次。
  • 标准边缘为各向同性5 mm;紧缩边缘为头尾和左右方向2 mm、前后方向3 mm。
  • 主要终点为放疗后90天急性毒性,采用CTCAE 5.0版GU和GI最高评分。
  • 患者报告结局采用EPIC-26泌尿和肠道领域评分。

临床怎么用

  • 对于局限期前列腺癌SBRT,将PTV边缘从5 mm缩小至2-3 mm似乎未降低急性GU和GI毒性。
  • 患者报告的泌尿刺激/梗阻生活质量在1个月时虽有统计学显著升高但未达临床显著。
  • 实时全面运动管理和前列腺门控可能进一步降低GU和GI毒性并改善治疗相关生活质量。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: A sub-fractionation workflow to correct for intrafraction motion in localized prostate cancer radiotherapy was implemented at our center, allowing for PTV margin reduction from isotropic 5 mm to 2 mm in cranio-caudal and left-right directions and 3 mm in the anterior-posterior direction. The purpose of this study was to assess differences in acute toxicity before and after margin reduction. MATERIALS AND METHODS: Included patients were treated with 36.25 Gy in five fractions on a 1.5 T MR-linac, with PTV margins of 5 mm (standard margins) or 2-3 mm (tight margins). The primary endpoint was acute (90 days post-RT) toxicity. Physician-reported toxicity was measured by maximum CTCAE version 5.0 genitourinary (GU) and gastrointestinal (GI) scores. Patient reported toxicity was a secondary endpoint, assessed through EPIC-26 urinary and bowel domain scores. Groups were balanced through propensity score matching after multiple imputation using chained equations. Pearson's Chi-squared tests were used to analyze CTCAE scores and Wilcoxon rank sum tests to analyze EPIC-26 scores. RESULTS: 299 eligible patients were identified (193 and 106 in the tight and standard margin groups, respectively). After matching, 212 patients (106 per treatment group) were available for assessment. No statistically significant between-group differences in physician-reported toxicity were observed at any follow-up point. Patient-reported urinary irritative/obstructive quality of life was statistically, but not clinically, significantly higher after one month. Overall, scores declined during treatment and one month post-RT, but returned to baseline levels three months post-RT. CONCLUSION: Margin reduction below 5 mm did not seem to reduce acute toxicity after radiotherapy with a stereotactic body radiotherapy (SBRT) treatment schedule in localized prostate cancer. The introduction of real-time comprehensive motion management with prostate gating could further lower GU and GI toxicity and ameliorate treatment related quality of life.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Lalmahomed TA, Willigenburg T, van de Pol SMG, et al. Acute toxicity and quality of life after margin reduction using a sub-fractionation workflow for stereotactic radiotherapy of localized prostate cancer on a 1.5 Tesla MR-linac. Radiother Oncol. 2025. PMID: 40089162. doi:10.1016/j.radonc.2025.110845

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。